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ABSTRACT
Objective: The goal of this study was to estimate an algo-
rithm to convert responses to the Functional Assessment of
Cancer Therapy—General (FACT-G) to time trade-off (TTO)
utilities based on utilities for current health elicited from
cancer patients.
Methods: Data for 1433 cancer patients were randomly
separated into construction and validation samples. Four
FACT-G questions were selected for inclusion based on cor-
relation with Eastern Clinical Oncology Group—
Performance Status (ECOG-PS) scores and TTO utilities.
Item response theory was used to collapse response catego-
ries. Ordinary least squares regression with the constant con-
strained to one was used to estimate the algorithm.
Results: The algorithm estimated mean utility for the full
validation sample within three points of observed mean
utility (0.805 vs. 0.832, P < 0.01). Mean utilities were well
predicted (mean absolute difference < 0.03, P > 0.05) for
most subgroups deﬁned by ECOG-PS and Short Form-36
physical functioning scores, and responses to the FACT-G
overall quality of life item. Nevertheless, the algorithm sys-
tematically overpredicted utilities for poorer health states.
Conclusions: A FACT-G-based algorithm of cancer patient
utilities was developed that estimates group mean utility
scores with accuracy comparable to other indirect preference-
based measures of health-related quality of life. Patient-based
preferences for health outcomes of cancer treatment may be
useful in multiple situations, such as managing resources
within cancer centers and in understanding health states pref-
erences among cancer experienced patients before and after
treatment.
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Introduction
The EQ-5D [1,2] and Health Utilities Index [3,4] are
generic measures of health-related quality of life
(HRQL) with societal reference weights for their clas-
siﬁcation systems that can help to inform health-care
resource allocation. Some measures, like the Short
Form (SF)-36 and SF-12, have been adapted for this
purpose as well [5–7]. In addition, a set of societal
preference-weights were recently derived for the Func-
tional Assessment of Cancer Therapy—Lung Cancer
[8], an HRQL measure often included in clinical trials
with a quality of life end point [9].
The use of societal preference weights in HRQL
measurement is supported by the notion that it is the
general population, that is, (tax) payer, who ultimately
pays for a given medical technology, so their prefer-
ences should be used in reimbursement decisions. This
argument is most tenable in a socialized health-care
environment. In privatized health-care systems, the
ability to calculate utility-based HRQL scores derived
from cancer-experienced individuals may be an impor-
tant complement to societal-based preference weights
in informing decision-making, particularly for clinical
decisions in cancer. Because patient preferences are
known to differ systematically from community pref-
erences, information regarding patient preferences can
help the clinician describe how patients feel about a
treatment option, and determine what the optimal
treatment decision would be for an individual or group
of patients at his/her clinic. Finally, the use of patient
preferences can help in identifying when a patient is an
outlier relative to group-based preferences.
In the ﬁeld of oncology, the EORTC-QLQ30
and the Functional Assessment of Cancer
Therapy—General (FACT-G) are the most widely
translated and used cancer-focused HRQL instru-
ments. These measures are frequently incorporated in
clinical trials of cancer therapies. Nevertheless, neither
instrument provides a preference-based score. The
purpose of our study was to understand which aspects
of the FACT-G [10] were signiﬁcant predictors of
cancer-experienced patient utilities. The FACT-G
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consists of items and domains that are considered
important to cancer-experienced patients. The results
of this study delineate a subset of FACT-G items and
levels related to utility (based on the time trade-off
[TTO]) in terms of willingness to trade life-years as
expressed by patients. The resultant algorithm may be
useful as an alternative or complement to societal
preference-weights when comparing outcomes of
treatment in cancer either for clinical or economic
decision-making purposes.
Methods
This study is a retrospective study of data collected
prospectively for a prior quality of life study (National
Cancer Institute R01 CA60068). The algorithm was
based on directly elicited TTO utilities provided by a
large sample of cancer patients for their current health
state and who also completed the FACT-G. The con-
struction and testing of the algorithm to map FACT-G
responses onto TTO utilities was conducted in four
steps. First, the eligible sample was randomly divided
into algorithm construction and validation samples of
equal size. Using the construction sample, FACT-G
questions and response categories were then selected to
maximize the model’s expected predictive ability over
a wide range of utility scores. Multiple regression
models were explored to test for possible differences in
predictive ability. The selected model was estimated
using the construction sample. Finally, out-of-sample
predictive ability was estimated using multiple group-
ings of subjects in the validation sample.
Data were drawn from the previously collected
sample of 1714 cancer and HIV/AIDS patients who
participated at ﬁve academic medical centers: Rush-
Presbyterian-St. Luke’s Medical Center, Robert H.
Lurie Cancer Center of Northwestern University, Fox
Chase Cancer Center, Johns Hopkins Oncology
Center, and Medical College of Ohio [11]. Inclusion
criteria for the original prospective quality of life study
were broad, and included able to read and speak
English, and diagnosis of cancer or HIV. Demographic
and clinical data were collected, in addition to ﬁve
health status questionnaires (two of which were used
in this article), and a TTO instrument. Each partici-
pant completed questionnaires only once. To maximize
the generalizability of the model, the additional exclu-
sion criteria applied to the sample for this retrospective
analysis were few, and included: 1) failure to complete
either the TTO and/or FACT-G questionnaires; 2)
failure to comprehend the TTO, as judged by the inter-
viewer; and 3) diagnosis of HIV. A small number of
subjects (21 in the full sample) stated that their current
health was worse than death, suggesting a utility < 0.
Utilities less than zero were set equal to zero for this
analysis.
Individuals were offered a choice between 1 year in
their current health deﬁned as their health over the
previous 2 weeks, or a speciﬁed amount of time less
than 1 year in perfect health. The amount of time in
perfect health was incrementally lowered until respon-
dents were indifferent between the year spent in their
current health state, and the speciﬁed length of time in
perfect health. The TTO was interviewer administered,
and a visual aid was used to assist in subject
understanding.
The FACT-G has established reliability and validity,
including sensitivity to change [10]. Summary scores
may be calculated for four dimensions: physical social,
emotional, and functional well-being, in addition to
the overall total score. Each question has ﬁve possible
responses and can be scored so that a ‘4’ indicates no
problems and a ‘0’ indicates worst possible problems
with respect to the particular item.
In addition to the TTO and FACT-G, patient-rated
Eastern Clinical Oncology Group—Performance
Status (ECOG-PS) was used in the selection of ques-
tions, and both ECOG-PS and selected SF-36 questions
were used in the model validation. These two instru-
ments were selected because they are primary patient
function and health status questionnaires typically
used in oncology clinical trials. The implication for
quality of life and current health utility of additional
variables, such as stage of disease and treatment status,
vary considerably across diagnoses, and were therefore
not used in the validation.
Questions were selected for inclusion in the algo-
rithm based in part on their correlation with the TTO
and ECOG-PS scores. Questions were also selected to
represent the full range of observed quality of life, by
ranking questions according to their mean scores, with
lower mean scores (representing worse health) receiv-
ing some preference for inclusion. Most questions did
not consistently perform best or worse by all criteria;
questions were therefore selected based on a subjective
application of the criteria. For example, a lower cor-
relation with the TTO was considered acceptable to
ensure that a question with a low mean score was
included, to better predict utilities for poor health.
One question (SWB—“social/family well-being”) was
excluded from consideration because of an observed
high number of missing responses in studies (subjects
are given the option to skip the question). In addition,
the ﬁnal question in the FACT-G (functional well-being
[FWB]—“am content with my QOL right now” was
excluded, because it is a global measure that is strongly
correlated with the remaining FACT-G questions. Cor-
relations between FACT-G questions were used to
identify questions that appeared to independently
predict utility.
Each FACT-G question has ﬁve possible response
categories, ranging from “not at all” to “very much.”
Response categories were combined to reduce the
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number of variables in the model. We examined the
rating scale structure of each item using a logistic
regression-based item response theory model and win-
steps [12], a computer software program for Rasch
measurement models. An acceptable rating scale struc-
ture was determined based on a number of criteria:
ﬁt statistic (mean square  1.4), ordered step calibra-
tion, nonskewed frequency distribution, and average
measure of categories. Misﬁtting response categories
were combined with other response categories where
appropriate. Response categories were further com-
bined as needed to ensure that the scales are mono-
tonic with respect to utility in the regression model.
Because the goal of the algorithm was to predict
mean utility, an ordinary least squares model was con-
ducted using the construction sample data to estimate
the mapping algorithm. Responses to the selected
FACT-G questions made up the full set of independent
variables. Each response was entered in to the model as
a dummy variable, with the best possible response set
as the reference case. Each variable coefﬁcient there-
fore represents a decrement in quality of life relative to
the best possible response on each item. To avoid a
disease labeling effect that could result from an algo-
rithm that predicts utility less than perfect health even
when there are no problems reported on the FACT
questions, the constant was constrained to one. Alter-
native model speciﬁcations were also conducted,
including the use of a quasi maximum likelihood logis-
tic model [13], and the use of mean utilities collected
for groups of patients with identical FACT responses
to the included questions.
The predictive ability of the algorithm was tested in
multiple ways using the portion of the data set aside
for validation. First, out-of-sample mean absolute
errors were calculated for each model. Next, subjects
in the validation sample were grouped according to a
number of variables that might be used to describe
patient outcomes in clinical trials or observational
studies, including SF-36 physical functioning and
mental health scales (with groups selected to ensure a
minimum of 30 subjects per group), and responses to
the ECOG-PS and general quality of life item of the
FACT-G. Statistical tests were conducted to identify
mean errors that were statistically different from zero.
Minimum clinically important differences (MCIDs)
have been either implicitly or explicitly proposed for
several generic indirect utility-based measures, with
fairly consistent proposed MCID benchmarks around
0.03 on a scale where 0 is dead and 1 is the upper end
point of the scale [14]. A difference of 0.03 has been
considered important on the Health Utilities Index
Mark 2 and Mark 3 [15] and a change or difference
score of 0.033 or more has been proposed as mean-
ingful for the SF-6D [16]. Any change in the level
reported on the EQ-5D been cited as potentially mean-
ingful [14], with the smallest coefﬁcient being approxi-
mately 0.03 in the widely applied Dolan algorithm [2].
Given the precedents in the literature, we considered a
difference of 0.03 to be meaningful.
Results
A total of 1714 subjects participated in the overall
project, of which 170 subjects did not have a diagnosis
of cancer. An additional 111 subjects did not complete
the interview, or were judged by the interviewer to be
unable to comprehend the interview. The remaining
sample included 1433 subjects, with one of 10 differ-
ent diagnoses, with other known cancer (n = 288),
breast cancer (n = 250), prostate cancer (n = 189),
colon cancer (n = 170), nonsmall cell lung cancer
(n = 146), head and neck cancer (n = 164), non-
Hodkins lymphoma (n = 148), Hodkins (n = 38),
small cell lung cancer (n = 35), and unknown primary
(n = 12). The sample was 53% male, with an average
age of 57 years (range 17–99 years). The sample was
racially diverse, including 83% white, non-Hispanic
subjects, 13% African American, non-Hispanic sub-
jects, and 3% Hispanic subjects. The sample was ran-
domly stratiﬁed in to two groups, with responses from
717 subjects used to construct the mapping algorithm,
and responses from the remaining 716 subjects used
for validation of the algorithm.
Table 1 displays the selected FACT-G questions,
along with their characteristics and rating scale
structure.
After a series of analyses, two items were revised to
a two-point rating scale, one to a three-point rating
scale, and one to a four-point rating scale. Overall, the
Table 1 Selected question characteristics
FACT-G item
Mean score
Correlation with
ECOG-PS
Correlation
with TTO
Response
category
Value Rank Value Rank Rank Value From 01234 to
PWB: lack of energy 2.29 1 -0.52 2 1 0.27 00112
PWB: feel sick 3.24 20 -0.44 1 6 0.29 01111
FWB: able to work 2.40 3 -0.47 10 4 0.22 00111
FWB: able to enjoy life 2.94 9 -0.36 6 10 0.24 00123
ECOG-PS, Eastern Clinical Oncology Group—Performance Status, as reported by patients; FACT-G, Functional Assessment of Cancer Therapy—General; FWB, functional
well-being; PWB, physical well-being;TTO, time trade-off utility.
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number of possible response categories was reduced
from 30 to 11, describing a total of 48 possible health
states.
Table 2 describes the regression results. All coefﬁ-
cients were negative, with greater reductions in
FACT-G responses (e.g., move from 4 to 0 vs. 4 to 3)
associated with greater reductions in utility. Most dec-
rements in quality of life described by the FACT-G
items were associated with statistically signiﬁcant
reductions in utility and each FACT-G response
changes was associated with a clinically important
reduction in utility of three percentage points or more.
The predictive ability of the model was tested by
estimating utilities for the 717 subjects that were set
aside. Validation sample predicted utilities are shown
in Table 3. Observed and predicted mean utilities are
within the three percentage points deﬁned as the
MICD (0.805 and 0.832, respectively), but the differ-
ence is statistically signiﬁcant (P < 0.01). The range
and standard deviation for the predicted utilities is
substantially less than for observed utilities (0 to 1,
standard deviation = 0.284 and 0.456 to 1, standard
deviation = 0.121, respectively), reﬂecting over predic-
tion of utilities for poor health. Observed and pre-
dicted utilities are reasonably well correlated (r = 0.32,
P < 0.01).
The predictive ability of the models was further
examined by calculating mean predicted utilities for
subjects grouped by various criteria. Subjects were
grouped according to ECOG-PS, by responses to the
FACT-G question, “I am content with the quality of
my life right now,” and two of the eight scales deﬁned
by the SF-36 (physical functioning and mental health).
For the SF-36 scales, subjects were grouped for each
Table 2 Regression results
FACT-G item Coefﬁcient
Standard
error
95% conﬁdence
interval
PWB: lack of energy
0–1 vs. 4 -0.22* 0.03 -0.28, -0.16
2–3 vs. 4 -0.11* 0.02 -0.15, -0.07
PWB: feel sick
0 vs. 1–4 -0.15† 0.06 -0.28, -0.03
FWB: able to work
0–1 vs. 2–4 -0.04‡ 0.03 -0.09, 0.01
FWB: able to enjoy life
0–1 vs. 4 -0.13† 0.04 -0.20, -0.05
2 vs. 4 -0.06‡ 0.03 -0.13, 0.00
3 vs. 4 -0.03 0.03 -0.09, 0.02
R2 0.17
MAE 0.19
*P < 0.01, †P < 0.05, ‡P < 0.10.
FACT-G, Functional Assessment of Cancer Therapy—General; FWB, functional well-
being; MAE, mean absolute error; PWB, physical well-being.
Table 3 Mean prediction error by group
Groups
Mean prediction
error Groups
Mean prediction
error
ECOG FACT-G: I am content with the quality of my life right now
Conﬁned to bed
(n = 7)
0.342* Not at all
(n = 90)
0.105*
Bed > 50%
(n = 79)
0.104* A little bit
(n = 69)
-0.025
Bed < 50%
(n = 233)
0.042* Somewhat
(n = 170)
0.012
Some symptoms
(n = 189)
0.007 Quite a bit
(n = 172)
0.016
No symptoms
(n = 209)
-0.010 Very much
(n = 184)
-0.004
SF-36: physical functioning (PF) SF-36: mental health (MH)
0 PF < 10
(n = 30)
0.139* 0MH < 40
(n = 32)
0.004
10 PF < 20
(n = 30)
0.107† 40MH < 50
(n = 54)
-0.006
20 PF < 30
(n = 42)
0.006 50MH < 60
(n = 53)
0.024
30 PF < 40
(n = 56)
0.011 60MH < 70
(n = 138)
0.026
40 PF < 50
(n = 52)
0.042 70MH < 80
(n = 92)
0.010
5 PF < 60
(n = 85)
0.027 80MH < 90
(n = 188)
0.011
60 PF < 70
(n = 60)
0.019 90MH < 100
(n = 105)
0.017
70 PF < 80
(n = 87)
0.013
80 PF < 90
(n = 94)
-0.004
90 PF < 100
(n = 95)
0.000
*P < 0.05; †P < 0.10.
ECOG, Eastern Clinical Oncology Group; FACT-G, Functional Assessment of Cancer Therapy—General; SF-36, Short Form-36.
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according to their scale score in 10-point increments,
with groups combined as appropriate to ensure 30
subjects per group.) Prediction results are shown in
Table 3.
Mean utilities are well predicted (difference less
than three percentage points, and difference not statis-
tically signiﬁcant) for most subject subgroups. Mean
utilities for subject groups deﬁned by the relatively
broad ECOG-PS measure differs signiﬁcantly for the
three lowest functioning subgroups. Differences for the
remaining three measures are not statistically and clini-
cally meaningful for any of the subgroups except for
the two lowest functioning by the SF-36 physical func-
tioning measure and for the lowest functioning by the
FACT-G overall quality of life item. In most cases, the
algorithm overpredicts utilities. This is especially true
for the poor health subgroups.
Use of the algorithm to estimate utilities requires
that response categories ﬁrst be collapsed, and con-
verted in to sets of dummy variables for application of
the regression equation. This is accomplished using the
cross-walk equation below. All variables must be
ordered so that a 0 indicates the worst possible
response, so that two of the selected questions (physi-
cal well-being [PWB]: lack of energy and PWB: feel
sick) should be reversed ﬁrst.
Utility = +
− = [ ]
− = [ ]
⎛⎝⎜ ⎞⎠⎟ +
−
1
0 2222 0 1
0 1137 2 3
0 1537
.
.
.
if q1 ,
if q1 ,
if q2
if q3 ,
if q4 ,
if q4
=( ) +
= [ ]( ) +
− = [ ]
− =
0
0 0431 0 1
0 1254 0 1
0 0641
.
.
. 2
0 0345 3− =
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟
. if q4
Where q1 = PWB: lack of energy, q2 = PWB: feel sick,
q3 = FWB: able to work, and q4 = FWB: able to enjoy
life. Group mean utilities can be estimated by ﬁrst
calculating individual predicted utilities, and then aver-
aging within the group. Because this is a linear model,
group means can also be calculated by multiplying
each coefﬁcient by its percentage frequency (i.e., if
responses are evenly divided by three for the ﬁrst ques-
tion, each coefﬁcient would be multiplied by one-
third). STATA code to estimate utilities is available by
request.
Conclusions
The derivation of a set of utility-based weights based
on the FACT-G descriptive system serves multiple pur-
poses. First, an algorithm that generates a utility-based
single summary score from responses to the FACT-G
enables cost-utility analysis to be performed on both
retrospective and prospective FACT-G data sets.
Second, prospective data collection may be conducted
without the inclusion of direct preference elicitation
methods, such as the standard gamble or TTO, which
some subjects ﬁnd difﬁcult to understand [17–19].
It is important to note that the US Panel suggested
the use of community preferences for health states as
“the most appropriate ones for use in a Reference Case
analysis [20].” Societal preference weights are desir-
able for decisions of allocative efﬁciency across health-
care systems. Nevertheless, when allocating resources
across cancer-based settings or as a complement to
societal weights, it may be desirable to have a set of
patient-based weights.
In this article, we have described the construction
and validation of an algorithm to estimate cancer-
experienced patient preferences for health states
deﬁned by observed responses to the FACT-G. The
algorithm performed well in predicting mean utility in
a set-aside validation sample by multiple measures,
especially in the mid to high ranges of health. Mean
predicted values were generally quite close to observed
mean utilities for subject groupings deﬁned by
responses to four HRQL items.
The use of patient preferences, which are known to
be higher than community preferences, has the dis-
advantage empirically of reducing the variation of
observed utility, and limiting the number of FACT-G
items and response levels that can be included with
statistically and clinically meaningful coefﬁcients. Nev-
ertheless, the systematic overestimation of utility for
poor health states demonstrated in this study has also
been reported previously for algorithms that were
based on community preferences [7–12].
In this study, actual observed utilities for current
health were used rather than utilities for hypothetical
health states derived from the FACT-G questions. This
has the advantage of enabling us to predict actual
quality of life as measured by directly elicited TTO
utilities for current health, which is a goal of many
studies that cannot otherwise include direct elicitation
of utilities in the battery of assessments. A disadvan-
tage is that it results in greater individual prediction
error (as evidenced by the high mean absolute error).
Because group means are typically used in cost-utility
analyses and treatment comparisons, individual pre-
diction error is of less concern than any systematic
error predicting group means. Group mean prediction
was very accurate, usually within a few percentage
points of the directly observed TTO utility. Model
group mean error overall and for multiple subgroups
were usually within the range of differences commonly
observed between directly elicited utilities [21–23].
Therefore, mapping FACT-G scores to utilities for cal-
culation of group mean utilities seems justiﬁed by the
current study.
An additional strength of this study was that we had
a large enough sample size to partition the data to
include a validation sample. This allowed us to test the
270 Dobrez et al.
out-of-sample predictive ability of our models overall,
and for previously deﬁned subsets of patients, demon-
strating mean errors that were within the range of
those found in the Lawrence and Fleishman (2004)
models, which also tested out-of-sample predictive
ability for groups of patients overall, and by selected
characteristics [24].
Ultimately, the selection of FACT-G questions was
determined based on multiple factors; it is possible that
others would make different decisions using the same
data, potentially impacting the predictive ability of the
resulting model. Efforts to replicate the question selec-
tion in separate samples would be useful. Although the
model was estimated using cancer patients at all stages
of disease and treatment, the number of people with
self-reported very poor health was small, with only 12
subjects (<1%) reporting an ECOG-PS of 4 (conﬁned
to bed) in the overall analytic sample. Oversampling of
patients with relatively poor health would be helpful in
the future to improve the predictive ability of the
model for low utilities. Finally, the original assessment
of utility did not allow for values of current health that
were worse than death. Responses for subjects who
stated this preference were arbitrarily assigned a score
of -1, with no attempt made to elicit strength of pref-
erence. For this study, their scores were set equal to 0.
Nevertheless, there is considerable evidence that some
states of health are viewed as worse than death
[25,26], and some preference-based measures of utility,
such as the EQ-5D, explicitly allow for this in their
estimation of utility. Rescaling of utility scores to allow
for valuations of states worse than death would alter
the mapping algorithm, but could not be explored with
the data available for this study.
In conclusion, although the use of individual utili-
ties predicted from FACT-G responses cannot be sup-
ported by these results, estimates of group mean utility
scores based on FACT-G responses in a cohort of
patients is justiﬁed by its accuracy as compared with
applications with other instruments. The algorithm
draws on data collected from cancer and so is appro-
priate for the estimation of current health utilities for
patients. The algorithm greatly expands the pool of
data available for use in cost-utility analyses and treat-
ment comparisons: FACT-G responses from previously
conducted observational studies and clinical trials can
be used to estimate utilities; and response burden can
be minimized in newly conducted studies without the
exclusion of utilities, simply by including the FACT-G
in the assessment protocol. Future research that
focuses on the estimation of a societal set of preference
weights for the FACT-G will help to complement the
FACT-G algorithm based on cancer patient preferences
presented in this article.
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